Lazard Capital Starts Aratana Therapeutics (PETX) at Buy
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/14/2026
- Nasdaq ends sharply lower as hot inflation data stirs rate-hike worries
- Oil prices gain on attacks in Saudi Arabia, Iran's new tactics to target tankers
- U.S. consumer prices rise by 3.7% year-on-year in September
- Bank of America stock falls on earnings miss
- Netflix cuts 1,000 jobs as streaming giant seeks to boost engagement
Tweet
Share
E-mailGet Alerts PETX Hot Sheet
Price: $4.92 --0%
Rating Summary:
7 Buy, 5 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 13 | Down: 12 | New: 90
Rating Summary:
7 Buy, 5 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 13 | Down: 12 | New: 90
Join SI Premium – FREE
Lazard Capital initiates coverage on Aratana Therapeutics (NASDAQ: PETX) with a Buy. PT $28.00.
For an analyst ratings summary and ratings history on Aratana Therapeutics click here. For more ratings news on Aratana Therapeutics click here.
Shares of Aratana Therapeutics closed at $10.12 yesterday.
For an analyst ratings summary and ratings history on Aratana Therapeutics click here. For more ratings news on Aratana Therapeutics click here.
Shares of Aratana Therapeutics closed at $10.12 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- UBS Starts Viking Therapeutic (VKTX) at Buy
- UBS Starts Ultragenyx Pharma (RARE) at Neutral
- RBC Capital Assumes OR Royalties Inc. (OR) at Outperform
Create E-mail Alert Related Categories
Hot New Coverage, New CoverageRelated Entities
LazardSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
